4/17
04:15 pm
jazz
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
Low
Report
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
4/17
04:15 pm
jazz
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
Low
Report
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
4/16
05:12 am
jazz
Acute Lymphocytic Leukemia (ALL) Pipeline Landscape Report 2024: Comprehensive Insights About 250+ Companies and 250+ Pipeline Drugs [Yahoo! Finance]
Low
Report
Acute Lymphocytic Leukemia (ALL) Pipeline Landscape Report 2024: Comprehensive Insights About 250+ Companies and 250+ Pipeline Drugs [Yahoo! Finance]
4/15
04:39 am
jazz
Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off [Seeking Alpha]
Medium
Report
Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off [Seeking Alpha]
4/10
10:19 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $180.00 price target on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $180.00 price target on the stock.
4/10
08:01 am
jazz
Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting [Yahoo! Finance]
4/10
07:45 am
jazz
Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting
Low
Report
Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting
4/2
07:39 am
jazz
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer [Yahoo! Finance]
4/2
07:30 am
jazz
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
Low
Report
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
3/29
12:57 pm
jazz
Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report? [Yahoo! Finance]
3/28
10:34 am
jazz
Cancer and the Combination Approach [Yahoo! Finance]
Low
Report
Cancer and the Combination Approach [Yahoo! Finance]
3/28
09:16 am
jazz
AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING [Yahoo! Finance]
Low
Report
AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING [Yahoo! Finance]
3/28
07:09 am
jazz
Mythic Therapeutics Appoints George Eliades, Ph.D., as President and Chief Executive Officer [Yahoo! Finance]
Low
Report
Mythic Therapeutics Appoints George Eliades, Ph.D., as President and Chief Executive Officer [Yahoo! Finance]
3/25
01:07 pm
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at JPMorgan Chase & Co. from $170.00 to $190.00. They now have an "overweight" rating on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at JPMorgan Chase & Co. from $170.00 to $190.00. They now have an "overweight" rating on the stock.
3/22
02:32 pm
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $180.00 price target on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $180.00 price target on the stock.
3/21
08:14 am
jazz
The Leadership Development Group Releases Guide on Talent Management Strategies For Post-Milestone Growth [Yahoo! Finance]
Low
Report
The Leadership Development Group Releases Guide on Talent Management Strategies For Post-Milestone Growth [Yahoo! Finance]
3/20
12:31 pm
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $200.00 price target on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $200.00 price target on the stock.
3/20
10:29 am
jazz
Jazz Pharmaceuticals Celebrates International Women's Day [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals Celebrates International Women's Day [Yahoo! Finance]
3/20
08:08 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $220.00 price target on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $220.00 price target on the stock.
3/20
08:08 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at Piper Sandler from $171.00 to $188.00. They now have an "overweight" rating on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at Piper Sandler from $171.00 to $188.00. They now have an "overweight" rating on the stock.
3/18
03:52 pm
jazz
20 States with the Cheapest Weed in America [Yahoo! Finance]
Low
Report
20 States with the Cheapest Weed in America [Yahoo! Finance]
3/18
03:09 pm
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at HC Wainwright from $204.00 to $200.00. They now have a "buy" rating on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at HC Wainwright from $204.00 to $200.00. They now have a "buy" rating on the stock.
3/18
03:01 pm
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at Stifel Nicolaus from $225.00 to $230.00. They now have a "buy" rating on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at Stifel Nicolaus from $225.00 to $230.00. They now have a "buy" rating on the stock.
3/15
08:23 am
jazz
TSC Alliance® to Host 23rd Annual Comedy for a Cure® on April 14 in Los Angeles [Yahoo! Finance]
Low
Report
TSC Alliance® to Host 23rd Annual Comedy for a Cure® on April 14 in Los Angeles [Yahoo! Finance]
3/14
12:22 pm
jazz
Exploring How Jazz Pharmaceuticals Honored U.S. Black History Month [Yahoo! Finance]
Low
Report
Exploring How Jazz Pharmaceuticals Honored U.S. Black History Month [Yahoo! Finance]